Thursday, October 15, 2026

Corporate Investments

2 articles

Semiconductor Companies Pursue AI Accelerator R&D as Lattice Guides Q1 Revenue $158M-$172M Amid Market Pressures

Semiconductor Companies Pursue AI Accelerator R&D as Lattice Guides Q1 Revenue $158M-$172M Amid Market Pressures

Lattice Semiconductor forecasts Q1 revenue of $158M-$172M as chipmakers navigate DRAM oversupply and geopolitical disruptions. Despite near-term headwinds, companies are investing in next-generation AI accelerators and advanced memory technologies to address von Neumann bottleneck limitations. InspireSemi develops high-performance computing solutions for AI workloads while Wolfspeed expands into EV platforms through OEM partnerships.

ViaNews Editorial Team (Finance)•
Nvidia Deploys $2B Across Photonics Suppliers to Solve AI Data Bottlenecks

Nvidia Deploys $2B Across Photonics Suppliers to Solve AI Data Bottlenecks

Nvidia is investing $2 billion in photonics partnerships with Coherent and Lumentum to address data transfer limitations in AI infrastructure. The strategic shift comes as semiconductor firms report strong AI-driven demand from data centers, though the industry faces $5-7 trillion capital requirements over five years. Traditional chipmakers continue standard product cycles while specialized suppliers position for AI buildout opportunities.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com